Clinical Safety and Tolerability of gpASIT+TM Administered Subcutaneously in Absence or in Presence of DnaK Immunoregulating Adjuvant for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis.

Trial Profile

Clinical Safety and Tolerability of gpASIT+TM Administered Subcutaneously in Absence or in Presence of DnaK Immunoregulating Adjuvant for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2011

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary) ; Adjuvants
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top